GP-100 antigen

DB14800InvestigationalProtein Based Therapies

GP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).

Mechanism: Pharmacologically active on Melanocyte protein PMEL
Curator reviewed
Also known as: Gp100 adenoviral gene therapy · GP100 ANTIGEN · MELANOCYTE PROTEIN PMEL · Melanocyte protein Pmel 17 · MELANOCYTES LINEAGE-SPECIFIC ANTIGEN GP100
Code names: Ad2CMV-gp100 · Ad2/gp100v2

Resolves to

Compound

UNII1NU720978F

Targets

P40967PMEL

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with GP-100 antigen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account